Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
Pfizer presented Phase 3 TRANQUILLO results showing LITFULO significantly improved facial and total body repigmentation in nonsegmental vitiligo at Week 52 versus placebo, with both co-primary endpoints met. F-VASI75 was achieved by 21.86% (100 mg) and 12.47% (50 mg) of patients versus roughly 2.4% on placebo, and the safety profile was consistent with the drug's established alopecia areata label with no new safety signals.
Key figures
- Drug Name
- LITFULO (ritlecitinib)
- Phase Of Trial
- Phase 3
- Sites
- 271
- Fvasi75 50mg
- 12.47%
- Tvasi50 50mg
- 8.98%
- Endpoint week
- 52
- Fvasi75 100mg
- 21.86%
- Tvasi50 100mg
- 13.02%
- Patients enrolled
- 2174
- Fvasi75 placebo study1
- 2.48%
- Fvasi75 placebo study2
- 2.40%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.